Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study.
Richard Greil
No relevant relationships to disclose
Roger Von Moos
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen
Expert Testimony - Amgen
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Honoraria - Roche
Pia J. Osterlund
Consultant or Advisory Role - Roche
Honoraria - Roche
Thierry André
Consultant or Advisory Role - Amgen; Roche
Honoraria - Baxter ; Merck; Sanofi
Eric Van Cutsem
Research Funding - Roche
Stefan Kubicka
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche; Sanofi
Dirk Arnold
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Roche
Jose Maria Vieitez de Prado
No relevant relationships to disclose
Olivier Bouche
Consultant or Advisory Role - Roche
Honoraria - Roche
Vicente Alonso
No relevant relationships to disclose
Christophe Borg
No relevant relationships to disclose
Christoph Schlichting
No relevant relationships to disclose
Claus-Christoph Steffens
Consultant or Advisory Role - Roche
Honoraria - Roche
Stuart Osborne
Employment or Leadership Position - Roche
Daniel Waterkamp
Employment or Leadership Position - Roche
Martina Makrutzki
Employment or Leadership Position - Roche
Javier Sastre
Honoraria - Roche
Research Funding - Roche